Early-onset colorectal cancer in young individuals.

Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. · 2019

Read Early-onset colorectal cancer in young individuals. by Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6360363.txt.

Introduction

Mauri and co-authors review early-onset colorectal cancer in Molecular Oncology. Cases in adults under fifty have risen about two percent per year since 1994. That rise stands out because rates in older adults have been falling.

Young patients often learn of the disease at a late stage. Their tumors tend to sit in the left colon and grow in more aggressive forms. About thirty percent carry an inherited cancer syndrome, and twenty percent have family cases. Half have neither clear cause. The authors call for better awareness and for care paths built for young patients.

Catalog record

CREATORMauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE81 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6360363

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Early‐onset colorectal cancer in young individuals By Gianluca Mauri, Andrea Sartore‐Bianchi, Antonio‐Giampiero Russo, Silvia Marsoni, Alberto Bardelli, Salvatore Siena Published in: Molecular Oncology DOI: 10.1002/1878-0261.12417 ABSTRACT Abstract Treatment of young adults with colorectal cancer (CRC) represents an unmet clinical need, especially as diagnosis in this population might lead to the greatest loss of years of life. Since 1994, CRC incidence in individuals younger than 50 years has been increasing by 2% per year. The surge in CRC incidence in young adults is particularly alarming as the overall CRC frequency has been decreasing. Early‐onset CRC are characterized by a more advanced stage at diagnosis, poorer cell differentiation, higher prevalence of signet ring cell histology, and left colon‐sided location of the primary tumor. Among EO‐CRC, approximately 30% of patients are affected by tumors harboring mutations causing hereditary cancer predisposing syndromes, and 20% have familial CRC. Most notably, the remaining 50% of EO‐CRC patients have neither hereditary syndromes nor familial CRC, thus representing a formidable challenge for research. In this review article we summarize epidemiology, clinical and molecular features, heredity and outcome of treatments of EO‐CRC, and provide considerations for future perspectives. Keywords: colorectal cancer, familial colorectal cancer, hereditary colorectal cancer, sporadic early‐onset colorectal cancer, young adults AbbreviationsAYAadolescent and young adultCIMPCpG island methylator phenotypeCINchromosomal instabilityCRCcolorectal cancerEO‐CRCearly‐onset colorectal cancerFAPfamilial adenomatous polyposisFOBTfecal occult blood testLSLynch syndromeMACSmicrosatellite and chromosome stableMAPMutYH‐associated polyposismCRCmetatastic colorectal cancerMMRmismatch repairMSImicrosatellite instabilityNAPNTHL1‐associated polyposisOSoverall survivalPAPPpolymerase proofreading‐associated polyposisPFSprogression‐free survivalRRResponse rateSEERsurveillance, epidemiology and end results program INTRODUCTION Colorectal cancer (CRC) is the third most common cancer and cause of cancer death worldwide in both genders (Siegel et al., 2018). At diagnosis, the median age of patients with colon cancer is 68 and 72 years in men and women, respectively; the median age of patients with rectal cancer is 63 years in both genders (American Cancer Society. Colorectal Cancer Facts & Figures, 2017; Siegel et al., 2018). In recent years, the overall CRC incidence and mortality in the USA and Europe has dropped (Malvezzi et al., 2018; Siegel et al., 2018). Since the mid‐2000s, CRC incidence in the USA has decreased by 2–3% per year in men and women (American Cancer Society. Colorectal Cancer Facts & Figures, 2017; Siegel et al., 2018). This reduction has been mainly correlated with the spread of screening tests [fecal occult blood test (FOBT) and colonoscopy] allowing detection and excision of premalignant lesions, and to a higher awareness of CRC risk factors among the population (Holme et al., 2013; Siegel et al., 2018; Welch and Robertson, 2016). Since 2012 in Europe, the CRC mortality rate decreased by 6.7% in men and 7.5% in women, whereas between 2008 and 2016, CRC incidence increased by 6% annually (Malvezzi et al., 2018; Vuik et al., 2018). Overall survival (OS) at 5 years from diagnosis is around 60% considering all stages of disease (Siegel et al., 2018; Van Cutsem et al., 2014). Metastatic CRC, despite therapeutic advances, exhibits poor prognosis; with the present state of the art, only 14% of patients are alive after 5 years from diagnosis (Siegel et al., 2018; Van Cutsem et al., 2014). In 2010, CRC among patients < 50 years old accounted for 4.8% and 9.5% of colon and rectal cancers, respectively (Bailey et al., 2015; Silla et al., 2014). Interestingly, recent studies on several continents have reported an increase in CRC incidence in this age subset and especially in individuals < 40 years (Bailey et al., 2015; Bleyer et al., 2017; Exarchakou et al., 2018; Hessami Arani and Kerachian, 2017; Troeung et al., 2017), including also the metropolitan area of Milan, Italy (A.‐G. Russo, A. Andreano, A. Sartore‐Bianchi, G. Mauri, A. Decarli & S. Siena, personal communication). To date, the actual magnitude and the underlying etiologies of this increase are unclear. Diagnostic and therapeutic protocols dedicated to early‐onset CRC (EO‐CRC) in young individuals are a currently unmet clinical need. Also, there is no consensus on whether EO‐CRCs are undistinguishable or are a distinct molecular/immunologic entity from CRC in older patients (Bleyer et al., 2017; Luzzatto and Pandolfi, 2015; Tomasetti and Vogelstein, 2015; Tricoli et al., 2016). In this article, we critically review clinical and molecular characteristics of EO‐CRC based on retrospective analyses, clinical trials, books and reviews currently available in the scientific literature. A systematic review approach has been applied for prognosis and standard metastatic colorectal cancer (mCRC) molecular biomarkers (RAS and BRAF) prevalence among EO‐CRC. MATERIALS AND METHODS We first performed a narrative review of clinical and pathological characteristics of EO‐CRC, retrieving articles through PubMed database, American Society of Clinical Oncology, European Society for Medical Oncology, and United European Gastroenterology meeting libraries, websites www.cancer.org and https://seer.cancer.gov/statfacts, and the book Cancer in Adolescents and Young Adults – Chapter 13. Secondly, according to PRISMA Criteria Statement 2009 (Fig. 1; Moher et al., 2009) we systematically retrieved articles describing EO‐CRC prognosis compared with older counterparts, and ther prevalence of RAS and BRAF mutations through PubMed database using [young(Title) OR younger(Title) OR early‐onset(Title) OR adolescent(Title) OR association of age(Title)] AND [colon(Title) OR rectal(Title) OR colorectal(Title)] AND [cancer(Title)] as search terms. Articles published in languages other than English, published earlier than year 2000, articles with a follow up shorter than 2 years, articles including patients older than 50 years of age in the younger group, and articles not comparing young with old patients in the same cohort were not included in the systematic review. This search was implemented by further manual revision of the bibliography of the included articles. [Figure: PRISMA 2009 flow diagram depicting the systematic review process performed to retrieve articles on prognosis and RAS and BRAF prevalence among EO‐CRC.] Definition of age groups 2.1. An unequivocal definition of ‘EO‐CRC’, or ‘young adult CRC’, is currently needed, as no clear and widely accepted consensus is available in literature or guidelines. According to a non‐pediatric oncology definition, the definition generally comprises all CRCs diagnosed before the screening age, i.e. < 50 years of age. Most screening programs start from this age chosen based on cost‐effective analyses of healthcare system sustainability. In contrast, in Adolescent and Young Adult (AYA) Oncology, it comprises CRC patients diagnosed at 15–29 years of age (Bleyer et al., 2017). Nevertheless, in the context of some AYA clinical trials, the age range has been extended to 50 years by the Children's Oncology Group (Bleyer et al., 2017). The US National Cancer Institute (NCI) Progress Review Group of AYA Oncology in 2006 proposed the age range of 15–39 years (Bleyer et al., 2017; Coccia et al., 2018). The definition of ‘very EO‐ CRC’ has also no clear consensus in the literature, with extreme variability among different publications. Therefore, definition of age groups among CRC patients is currently based on non‐specific epidemiologic screening or clinical trial accrual criteria. Current age‐group subdivision is indeed a limitation for interpreting results obtained from published molecular and clinical studies among EO‐CRCs. In this review, we included all publications dealing with EO‐CRC diagnosed before 50 years of age. A reasonable solution to improve future retrospective analyses of previously published studies in such a population of EO‐CRCs might be to consider age a continuous variable rather than using arbitrary predefined age cut‐offs (Lieu et al., 2014). The open question remains as to how to define age cut‐off for

Read the complete text